Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

Abstract Background Blinatumomab has shown a remission rate of 69% in an exploratory single-arm, phase II dose-escalation study in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). We evaluated changes in laboratory parameters and immunopharmacodynamic markers i...

Descripció completa

Dades bibliogràfiques

Autors principals:	Virginie Nägele, Andrea Kratzer, Gerhard Zugmaier, Chris Holland, Youssef Hijazi, Max S. Topp, Nicola Gökbuget, Patrick A. Baeuerle, Peter Kufer, Andreas Wolf, Matthias Klinger
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2017-05-01
Col·lecció:	Experimental Hematology & Oncology
Matèries:	Acute lymphoblastic leukemia Blinatumomab Bispecific BiTE® CD19 Liver enzymes
Accés en línia:	http://link.springer.com/article/10.1186/s40164-017-0074-5
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!